市場調査レポート
商品コード
1170394
ナルコレプシー市場:1次調査(KOLの洞察) - 市場インテリジェンス - 疫学と2032年までの市場予測Narcolepsy| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2032 |
ナルコレプシー市場:1次調査(KOLの洞察) - 市場インテリジェンス - 疫学と2032年までの市場予測 |
出版日: 2022年09月07日
発行: Mellalta Meets LLP
ページ情報: 英文 217 Pages
納期: 即納可能
|
世界のナルコレプシー治療薬の市場規模は、2018年~2032年にかけて、7.8%のCAGRで」拡大し、2032年までに50億米ドルに達すると予測されます。
当レポートでは、世界のナルコレプシー市場について調査し、市場の現状とともに、症例数の動向、患者動向、競合製品の市場における位置づけ、市場の機会などを提供しています。
The Narcolepsy market is hugely contributed by a very narrow range of treatment options available and only limited to the management of the symptoms. But currently, no medicine can cure Narcolepsy completely. By 2032, the market is expected to change due to the uptake and launch of new novel therapies. In a NARCOLEPSY treatment setting, the current SoC will increase along with the launch and uptake of novel emerging drugs while will drive market shares. The sales of the emerging therapies for the treatment of Narcolepsy in the study countries (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 5 billion by 2032.
"For decades, patients with narcolepsy have complained of depressive symptoms. In addition, the presence of [a] clinically defined major depressive episode, suicidal thoughts, and suicide risks have been seldom investigated in NT1, although sleep disturbances are often associated with suicidality".
Narcolepsy is a chronic neurological disorder that affects the brain's ability to control sleep-wake cycles. People with narcolepsy may feel rested after waking, but then feel very sleepy throughout much of the day. Many individuals with narcolepsy also experience uneven and interrupted sleep that can involve waking up frequently during the night. Narcolepsy affects both males and females equally. Symptoms often start in childhood, adolescence, or young adulthood (ages 7 to 25), but can occur at any time in life.
The total NARCOLEPSY prevalent cases in the G7 countries are anticipated to increase to 557,552 cases by 2032 for the study period (2018- 2032). As per estimates, Japan accounted for the highest prevalence of Narcolepsy cases in 2018 which was 212,004 cases and is expected to increase by 2032 for the study period. Among the EU5, Germany had the highest Narcolepsy cases, followed by the UK, France, Italy, and Spain. The United States is reported to have the highest number of treated cases after Japan, Germany, and the UK.
Current treatments for narcolepsy are currently aimed at controlling the principal symptoms: EDS, cataplexy, sleep fragmentation, sleep paralysis, and hypnagogic and hypnopompic hallucinations, but are not intended to cure the disease. However, the treatment does manage to significantly improve the quality of life.
The Narcolepsy therapeutics market is expected to experience high growth throughout our study period (i.e., 2018 to 2032) to USD 5 billion, representing compound annual growth (CAGR) of 7.8%.
The United States captured the highest market share in 2022 as compared to the European 5 countries and Japan. The increase in the diagnosis rate and the usage of the current standard of care for controlling the symptoms will drive the therapeutic market for narcolepsy. By 2032, the market share of the United States is expected to increase to USD 4 billion whereas European 5 countries and Japan will have USD XX billion and USD XX million market size in 2032, respectively.
Despite the progress in the understanding of mechanisms underlying this condition, there is currently no cure for narcolepsy. Available drugs are all symptomatic therapies and cannot change the pathophysiologic course of the disease. More than 90% of patients with narcolepsy require pharmacological treatment, usually needed lifelong.
The majority of patients receiving narcolepsy-related pharmacological therapy were treated with modafinil, which is a recommended first-line medication option for narcolepsy. These drugs that stimulate the central nervous system are the primary treatment to help people with narcolepsy stay awake during the day. The demand for stimulants and selective serotonin to manage narcolepsy will dominate the global narcolepsy drugs market in the begging.
In the 2018-2032 forecast period, we expect that with the launch of the new therapies, the current treatment landscape will expand, catering to the need for treatment of cataplexy, abnormal hallucinations or dream-like experiences, and excessive daytime sleepiness (EDS) associated with narcolepsy patients. The emerging therapies which are expected to enter the market from 2022-2032 period are LUMRYZ/Sodium oxybate (Avadel Pharmaceuticals), Reboxetine (Axsome Therapeutics, Inc.), Quilience/Mazindol extended release (NLS Pharmaceutics Ltd) and Samelisant (Suven Life Sciences).